The TRAF6 Knockout IPEC-J2 Cell Line is a genetically modified porcine intestinal epithelial cell line in which the TRAF6 gene has been disrupted using CRISPR/Cas9 genome editing. This knockout cell line serves as a robust in vitro model for dissecting TRAF6-dependent signal transduction and innate immune responses in intestinal epithelium.
IPEC-J2 is a spontaneously immortalized cell line derived from porcine jejunal epithelial cells. It retains key characteristics of primary intestinal epithelial cells, including the formation of polarized monolayers with functional tight junctions, expression of brush border enzymes, and responsiveness to microbial and inflammatory stimuli. These features make IPEC-J2 cells an essential tool for studying intestinal barrier function, nutrient absorption, and mucosal innate immunity in swine, a biomedically relevant model for human gastrointestinal physiology and infectious diseases.
TRAF6 encodes an E3 ubiquitin ligase and signal transduction adaptor that plays a central role in activating NF-??B and JNK pathways downstream of receptors such as TLR4, IL-1R, and RANK. Upon stimulation by ligands like LPS, IL-1??, or RANKL, TRAF6 catalyzes K63-linked autoubiquitination and polyubiquitination of substrates, recruiting the TAK1-TAB1-TAB2 complex. This event triggers phosphorylation of the IKK complex and MAPKKs (e.g., MKK4), leading to activation of NF-??B and JNK, respectively. Consequently, TRAF6 promotes transcription of pro-inflammatory cytokines (TNF-??, IL-6, IL-12) and other immune mediators. TRAF6 interacts with multiple signaling partners, including IRAK1, IRAK4, NEMO, TRAF2, and MyD88, anchoring it within key pathways such as TLR4/MyD88/IRAK4/IRAK1/TRAF6/TAK1/IKK/NF-??B.
In the context of IPEC-J2 cells, disruption of TRAF6 abolishes a critical node in innate immune signaling, impairing responses to microbial and cytokine challenges. This knockout model is particularly suited for examining how TRAF6-dependent pathways regulate intestinal epithelial barrier integrity, tight junction dynamics, and inflammatory gene expression during host-microbe interactions. Researchers can use this line to investigate the molecular basis of mucosal inflammation, infectious enteritis, and disorders like inflammatory bowel disease, where TRAF6-mediated NF-??B activation contributes to pathogenesis. Moreover, the model allows dissection of TRAF6 functions independent of other adaptors, such as MyD88 or TRAF2, enabling precise mechanistic studies.
This cell line supports a diverse array of experimental applications. Typical research uses include studies of host-microbe interactions, where assays such as bacterial adhesion/invasion, RT-qPCR for cytokine mRNA, and ELISA for secreted proteins delineate TRAF6’s role in pathogen sensing. Intestinal inflammation models can be established using LPS or IL-1?? stimulation, with downstream readouts like Western blotting for phosphorylated NF-??B and JNK, TEER measurements, and FITC-dextran permeability to assess barrier disruption. Immunofluorescence for tight junction proteins (e.g., occludin) and flow cytometry for surface receptor expression further enable detailed phenotypic profiling. The TRAF6 Knockout IPEC-J2 Cell Line is also a valuable platform for drug screening of anti-inflammatory compounds and transcriptomic analyses via RNA-seq. For technical assistance, contact Ascent Research.
